Menu
Menu
Leaders in translating NET biology into novel therapies
Citryll has leveraged its deep understanding of the pro-inflammatory effect of neutrophil extracellular traps (NETs) to develop therapeutics for the treatment of a broad range of inflammatory diseases.
Next generation therapeutics for treatment of inflammatory diseases
Our lead antibody, CIT-013, is a next generation therapeutic for the treatment of inflammatory diseases. With a unique dual mode of action, CIT-013 has demonstrated a powerful ability to inhibit NETosis and the pathogenic consequences of NETs. It has anti-inflammatory properties across multiple preclinical disease models and inhibits NET release in human volunteers. CIT-013 is currently in Phase I clinical development, and Phase IIa studies in Rheumatoid Arthritis and Hidradenitis Suppurativa are expected to start later this year.
The role of NETosis and NETs in disease
The pathogenic role of NETs in inflammatory diseases has been demonstrated by an increasing body of scientific literature. Citryll has prioritized RA and HS as therapeutic development areas for CIT-013.
Latest News
A Year in Review: An Interview with Citryll’s CEO
Celebrating his first year as CEO of Citryll, Eduardo offers a unique perspective on his journey so far. In this exclusive interview, he reflects on the past year's challenges, achievements, and strategic initiatives that have driven the company forward.
Read More
Citryll Completes Patient Dosing In The Repeat Dose Stage Of The Phase 1 Trial
The Phase 1 first-in-human trial is assessing the safety and tolerability of CIT-013. Part D of the Phase 1 trial is investigating the safety and tolerability of repeat dosing in 9 patient volunteers with rheumatoid arthritis (RA) and 3 healthy volunteers.
Read More
Citryll announces the appointment of Maarten Kraan as Chief Medical Officer
Dr. Kraan is a rheumatologist who brings more than 25 years of biopharmaceutical development experience. Dr. Kraan joins Citryll after his CMO role at AM-Pharma. Prior to that, he held various senior medical and R&D positions at Pierre Fabre S.A., AstraZeneca, Roche and Bristol Myers-Squibb.
Read More